Revolution Medicines Inc. announced FDA approval for its pancreatic cancer drug, Rasonque, a first-in-class RAS-selective inhibitor. This landmark approval, backed by strong Phase 3 trial data, has led to significant price target increases from multiple Wall Street firms and a surge in the company's stock price.
Revolution Medicines (RVMD) has received FDA approval for Rasonque, its pancreatic cancer drug, marking a significant milestone as the first approved targeted therapy from a new class of broad RAS-selective inhibitors. This approval is a major positive catalyst, validating over a decade of R&D and opening up a new market opportunity for the company. The drug's efficacy, demonstrated by a 60% reduction in death risk and nearly doubled median overall survival in trials, underpins the strong analyst upgrades and increased price targets. This event is highly positive for RVMD in the short term, driving stock price appreciation, and offers long-term growth potential as the company aims for global regulatory expansion. Traders see an immediate opportunity in the upward momentum and increased valuation.